<DOC>
	<DOC>NCT02549651</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.</brief_summary>
	<brief_title>MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023)</brief_title>
	<detailed_description>This is a multicenter, open-label, dose-escalation and dose-expansion study of MEDI4736 as monotherapy or in combination with either tremelimumab or AZD9150. The objectives are to describe any dose-limiting toxicities, determine the maximum tolerated dose, and evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of MEDI4736 as monotherapy or in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1. Age â‰¥ 18 years 2. Histologically confirmed relapsed or refractory diffuse large Bcell lymphoma (DLBCL) who have been treated with no more than 5 prior lines of therapy (dose escalation) or no more than 3 prior lines of therapy (dose expansion) , including at least 1 rituximabcontaining chemotherapy regimen 3. Eastern Cooperative Group (ECOG) performance status of 0 or 1 4. Measurable disease by International Working Group (IWG) response criteria for lymphoma 5. Adequate organ and marrow function 1. Previous immunemediated therapy 2. Prior autologous or allogeneic stem cell transplant. Subjects who received ASCT &gt;100 days prior to first dose and are ineligible for available curative options after failing ASCT are eligible. 3. Documented current central nervous system involvement 3. Active or prior documented autoimmune or inflammatory disease within 3 years, with some exceptions 4. Concurrent or prior conventional or investigational anticancer therapy, within 28 days prior to the first dose of study medication(s)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>tremelimumab</keyword>
	<keyword>AZD9150</keyword>
	<keyword>anti-PD-L1</keyword>
	<keyword>anti-CTLA-4</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>IMTC</keyword>
	<keyword>STAT3</keyword>
</DOC>